Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3086% below fair value
$2.38−0.17 (-6.67%)
Close on Nov 20, 2026Market cap $40.82MP/E –Yield –
Tonix Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tonix Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$158.11M. For fiscal 2025 it was -$103.21M. The highest annual figure on record is -$1.27M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$103.21M | – |
| FY2024 | Dec 31, 2024 | -$61.05M | – |
| FY2023 | Dec 31, 2023 | -$109.90M | – |
| FY2022 | Dec 31, 2022 | -$146.20M | – |
| FY2021 | Dec 31, 2021 | -$110.86M | – |
| FY2020 | Dec 31, 2020 | -$57.13M | – |
| FY2019 | Dec 31, 2019 | -$26.70M | – |
| FY2018 | Dec 31, 2018 | -$23.98M | – |
| FY2017 | Dec 31, 2017 | -$19.13M | – |
| FY2016 | Dec 31, 2016 | -$37.38M | – |
| FY2015 | Dec 31, 2015 | -$42.65M | – |
| FY2014 | Dec 31, 2014 | -$23.16M | – |
| FY2013 | Dec 31, 2013 | -$8.53M | – |
| FY2012 | Dec 31, 2012 | -$5.75M | – |
| FY2011 | Dec 31, 2011 | -$2.64M | – |
| FY2010 | Dec 31, 2010 | -$1.27M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.83M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.92M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$25.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$35.61M | – |
| Q1 FY2022 | Mar 31, 2022 | -$51.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$48.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$19.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.72M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.65M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.89M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.49M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.93M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.44M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.39M | – |
See a number that looks wrong?